. 2021 Feb 12;9(2):e001638. doi: 10.1136/jitc-2020-001638

Table 2.

Univariate and multivariate analyses of prognostic factors correlated with progression-free survival and overall survival

Variables	Progression-free survival						Overall survival
	Univariate			Multivariate			Univariate			Multivariate
	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
Gender (male vs female)	1.234	0.692–2.201	0.477				1.144	0.627–2.088	0.660
Age (<60 vs ≥60)	0.766	0.434–1.350	0.356				0.692	0.382–1.254	0.225
Pathology (AC vs MAC)	0.860	0.476–1.554	0.617				0.703	0.380–1.299	0.261
Anatomy (colon vs rectum)	1.020	0.559–1.861	0.948				1.397	0.719–2.715	0.324
Location (left vs right)	1.142	0.620–2.104	0.670				1.311	0.702–2.448	0.395
pT classification (T_1-3 vs T₄)	0.444	0.247–0.797	0.006	0.579	0.313–1.071	0.082	0.513	0.281–0.936	0.030	0.722	0.381–1.365	0.316
pN classification (N₀ vs N_1-2)	0.341	0.187–0.621	<0.001	0.579	0.305–1.102	0.096	0.316	0.168–0.596	<0.001	0.557	0.282–1.103	0.093
pM classification (M₀ vs M₁)	0.057	0.031–0.107	<0.001	0.105	0.052–0.213	<0.001	0.044	0.023–0.085	<0.001	0.075	0.036–0.159	<0.001
Clinical stage (I–II vs III–IV)	0.263	0.139–0.497	<0.001				0.234	0.118–0.463	<0.001
CEA (ng/mL) (<5 vs ≥5)	0.961	0.544–1.695	0.890				0.961	0.531–1.740	0.896
CA19-9 (kU/L) (<35 vs ≥35)	0.447	0.251–0.793	0.006	0.647	0.356–1.173	0.151	0.427	0.235–0.776	0.005	0.603	0.324–1.120	0.109
CMTM6 (low vs high)	2.267	1.276–4.029	0.005	1.833	1.005–3.343	0.048	2.483	1.353–4.559	0.003	1.953	1.040–3.669	0.037
PD-L1 (whole) ((−) vs (+))	1.679	0.837–3.371	0.145				1.517	0.750–3.071	0.247
PD-L1 (TS) ((−) vs (+))	2.302	1.174–4.514	0.015	1.528	0.762–3.065	0.233	2.046	1.034–4.049	0.004	1.259	0.618–2.564	0.525
PD-L1 (CC) ((−) vs (+))	0.972	0.506–1.869	0.933				0.869	0.448–1.687	0.678

P value <0.05 in bold is statistically significant.

(−), negative; (+), positive; AC, adenocarcinoma; CA19-9, carbohydrate antigen 19-9; CC, cancer cell; CEA, carcinoembryonic antigen; CMTM6, CKLF-like MARVEL transmembrane domain-containing 6; MAC, mucinous adenocarcinoma; PD-L1, programmed death-ligand 1; TS, tumor stroma.